

Karin Agnes Maria Jandeleit-Dahm

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8230751/publications.pdf>

Version: 2024-02-01

33
papers

2,471
citations

331670

21
h-index

395702

33
g-index

34
all docs

34
docs citations

34
times ranked

4043
citing authors

#	ARTICLE	IF	CITATIONS
1	Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Dapagliflozin Stabilizes Diabetes-Induced Atherosclerotic Plaque Instability. <i>Journal of the American Heart Association</i> , 2022, 11, e022761.	3.7	22
2	Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney disease. <i>Clinical Science</i> , 2022, 136, 167-180.	4.3	23
3	Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities. <i>Handbook of Experimental Pharmacology</i> , 2022, , 269-307.	1.8	4
4	Independent of Renox, NOX5 Promotes Renal Inflammation and Fibrosis in Diabetes by Activating ROS-Sensitive Pathways. <i>Diabetes</i> , 2022, 71, 1282-1298.	0.6	14
5	Specific NLRP3 Inhibition Protects Against Diabetes-Associated Atherosclerosis. <i>Diabetes</i> , 2021, 70, 772-787.	0.6	84
6	Renal Replacement Therapy in People With and Without Diabetes in Germany, 2010-2016: An Analysis of More Than 25 Million Inhabitants. <i>Diabetes Care</i> , 2021, 44, 1291-1299.	8.6	9
7	Oral Supplementation of an Alkylglycerol Mix Comprising Different Alkyl Chains Effectively Modulates Multiple Endogenous Plasmalogen Species in Mice. <i>Metabolites</i> , 2021, 11, 299.	2.9	16
8	Endothelin in diabetes-associated atherosclerosis: opportunity for NOX TM . <i>Cardiovascular Research</i> , 2021, 117, 987-989.	3.8	3
9	Targeted deletion of nicotinamide adenine dinucleotide phosphate oxidase 4 from proximal tubules is dispensable for diabetic kidney disease development. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 988-997.	0.7	9
10	A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerations. <i>Contemporary Clinical Trials</i> , 2020, 90, 105892.	1.8	29
11	Biomarkers of Inflammation and Glomerular Filtration Rate in Individuals with Recent-Onset Type 1 and Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4370-e4381.	3.6	11
12	Inhibitors of Advanced Glycation End Product (AGE) Formation and Accumulation. <i>Handbook of Experimental Pharmacology</i> , 2020, 264, 395-423.	1.8	30
13	Evaluating the efficacy and safety of GKT137831 in adults with type 1 diabetes and persistently elevated urinary albumin excretion: a statistical analysis plan. <i>Trials</i> , 2020, 21, 459.	1.6	12
14	NADPH Oxidase Inhibition: Preclinical and Clinical Studies in Diabetic Complications. <i>Antioxidants and Redox Signaling</i> , 2020, 33, 415-434.	5.4	41
15	Targeting oxidative stress and anti-oxidant defence in diabetic kidney disease. <i>Journal of Nephrology</i> , 2020, 33, 917-929.	2.0	38
16	Endothelial or vascular smooth muscle cell-specific expression of human NOX5 exacerbates renal inflammation, fibrosis and albuminuria in the Akita mouse. <i>Diabetologia</i> , 2019, 62, 1712-1726.	6.3	27
17	Modulation of Oxidative Stress in Cardiovascular Diseases. , 2019, , 237-253.		3
18	Lipoxins Regulate the Early Growth Response-1 Network and Reverse Diabetic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1437-1448.	6.1	48

#	ARTICLE	IF	CITATIONS
19	Metabolic Karma—The Atherogenic Legacy of Diabetes: The 2017 Edwin Bierman Award Lecture. <i>Diabetes</i> , 2018, 67, 785-790.	0.6	22
20	Lipoxins Protect Against Inflammation in Diabetes-Associated Atherosclerosis. <i>Diabetes</i> , 2018, 67, 2657-2667.	0.6	60
21	A causal link between oxidative stress and inflammation in cardiovascular and renal complications of diabetes. <i>Clinical Science</i> , 2018, 132, 1811-1836.	4.3	114
22	Cardiovascular Disease and Diabetic Kidney Disease. <i>Seminars in Nephrology</i> , 2018, 38, 217-232.	1.6	52
23	The emerging role of NADPH oxidase NOX5 in vascular disease. <i>Clinical Science</i> , 2017, 131, 981-990.	4.3	51
24	NADPH Oxidase Nox5 Accelerates Renal Injury in Diabetic Nephropathy. <i>Diabetes</i> , 2017, 66, 2691-2703.	0.6	119
25	Diabetes and Kidney Disease: Role of Oxidative Stress. <i>Antioxidants and Redox Signaling</i> , 2016, 25, 657-684.	5.4	410
26	The role of NADPH Oxidase in Vascular Disease — Hypertension, Atherosclerosis & Stroke. <i>Current Pharmaceutical Design</i> , 2015, 21, 5933-5944.	1.9	41
27	Dicarbonyl Stress in the Absence of Hyperglycemia Increases Endothelial Inflammation and Atherogenesis Similar to That Observed in Diabetes. <i>Diabetes</i> , 2014, 63, 3915-3925.	0.6	74
28	Macrophage Polarization in Obesity and Type 2 Diabetes: Weighing Down Our Understanding of Macrophage Function?. <i>Frontiers in Immunology</i> , 2014, 5, 470.	4.8	227
29	Transforming growth factor- β 1-mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b. <i>Kidney International</i> , 2014, 85, 352-361.	5.2	153
30	Role of Nox2 in diabetic kidney disease. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 304, F840-F848.	2.7	84
31	Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes. <i>Clinical Science</i> , 2013, 124, 191-202.	4.3	142
32	Post-Stroke Inhibition of Induced NADPH Oxidase Type 4 Prevents Oxidative Stress and Neurodegeneration. <i>PLoS Biology</i> , 2010, 8, e1000479.	5.6	377
33	Imatinib Attenuates Diabetic Nephropathy in Apolipoprotein E-Knockout Mice. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 363-373.	6.1	121